Effect of recombinant human endostatin combined with VP regimen on levels of tumor markers in peripheral blood of patients with advanced non small cell lung cancer

Abstract

Objective To study the effect of recombinant human endostatin (Endostar) combined with VP regimen (cisplatin and vindesine) on levels of tumor markers in peripheral blood of patients with advanced non small cell lung cancer (NSCLC). Methods Eight-four patients with advanced NSCLC admitted to our hospital were divided into control group and treatment group (with 42 cases in each group) according to different treatment plans. The patients in the control group were treated with VP regimen, while the patients in treatment group were treated with recombinant human endostatin combined with VP regimen. The curative effect, vascular endothelial growth factor (VEGF), serum tumor markers and adverse reactions were compared between the two groups. Results The disease control rate in the treatment group was 73.81%, while that in the control group was 42.86% (P 0.05). Conclusions Recombinant human endostatin combined with VP regimen can improve the short-term therapeutic effect on patients with advanced NSCLC, and reduce the levels of serum VEGF and tumor markers, with few side effects, is safe and effective. Key words: Recombinant human endostatin; VP regimen; Advanced non small cell lung cancer; Tumor marker